AbbVie's Rinvoq: A Patent Extension Goldmine
Update: 2025-09-11
Description
Big Pharma Victory: AbbVie's stock skyrockets as Rinvoq dodges generics until 2037! Discover how this patent extension buys AbbVie crucial time to develop future blockbuster drugs and potentially adds billions to Rinvoq's peak revenue. Is this a strategic masterstroke or a delay of the inevitable? Find out how this impacts AbbVie's future and the race for innovative medicines.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
